PMID- 24379028
OWN - NLM
STAT- MEDLINE
DCOM- 20140908
LR  - 20211021
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 99
IP  - 2
DP  - 2014 Feb
TI  - DC-based immunotherapy for hematological malignancies.
PG  - 117-22
LID - 10.1007/s12185-013-1496-4 [doi]
AB  - Great advances have been made in the treatment of hematological malignancies, but 
      achieving a definitive cure remains an elusive goal for the majority of patients. 
      Antigen-specific tumor immunotherapy has the potential to improve clinical 
      outcome in patients with such diseases by eradicating chemotherapy-resistant 
      tumor cell clones without damaging normal tissues. Dendritic cells (DCs) serve as 
      an essential link between the innate and the adaptive immune systems, acting as 
      key controllers of antigen-specific T cell responses. Molecular identification of 
      tumor-specific antigens recognized by T lymphocytes and technical advances in ex 
      vivo generation of human DCs has enabled us to develop DC-based tumor 
      immunotherapies (also called "DC vaccines"). To date, a large number of clinical 
      trials of DC vaccines have been conducted for a variety of tumors, including 
      hematological malignancies. Overall, these trials have demonstrated that DC 
      vaccines have excellent safety profiles, moderate immunological activity, and 
      mild clinical efficacy. To establish a role for DC vaccines in the treatment of 
      hematological malignancies, we need both to define patient populations that can 
      obtain clinical benefit from DC vaccines and to develop combination therapies 
      that augment clinical efficacy of DC vaccines. In this review, I will describe 
      current status of DC-based immunotherapy for hematological malignancies, and 
      discuss future perspectives in this field.
FAU - Kitawaki, Toshio
AU  - Kitawaki T
AD  - Department of Hematology and Oncology, Kyoto University Hospital, 54 Shogoin 
      Kawara-cho, Sakyo-ku, Kyoto, 606-8507, Japan, kitawaki@kuhp.kyoto-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20131231
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
SB  - IM
MH  - Cells, Cultured
MH  - Dendritic Cells/immunology/pathology/*transplantation
MH  - Hematologic Neoplasms/immunology/pathology/*therapy
MH  - Humans
MH  - *Immunotherapy, Adoptive
EDAT- 2014/01/01 06:00
MHDA- 2014/09/10 06:00
CRDT- 2014/01/01 06:00
PHST- 2013/12/08 00:00 [received]
PHST- 2013/12/16 00:00 [accepted]
PHST- 2013/12/15 00:00 [revised]
PHST- 2014/01/01 06:00 [entrez]
PHST- 2014/01/01 06:00 [pubmed]
PHST- 2014/09/10 06:00 [medline]
AID - 10.1007/s12185-013-1496-4 [doi]
PST - ppublish
SO  - Int J Hematol. 2014 Feb;99(2):117-22. doi: 10.1007/s12185-013-1496-4. Epub 2013 
      Dec 31.